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ABSTRACT 
Purpose: Current literature supports pharmacists effectively lower hemoglobin A1c (HbA1c) in diabetic patients. Little data exists on 
pharmacists’ effects on comorbidity management, patient satisfaction, or the financial viability of these positions. This study looked to 
assess the impact of pharmacists on diabetes management compared to usual care. 
Methods: This multi-site, two-part study includes a retrospective chart review of patients referred to the pharmacist versus usual care 
within a large academic health system. The pharmacists collaborated under a consult agreement with primary care physicians. The 
second part of the study assessed patient satisfaction through an abbreviated CG-CAHPS survey. 
Results: A total of 206 patients with diabetes for an average of 12 years were included. The average patient age was 62 years with 60% 
of patients identifying as female and 81% as African-American. Patients were enrolled in a 2:1 fashion with 138 patients in the 
pharmacist-management group. Average baseline HbA1c was 10.1% in the pharmacist-management group and 9.3% in the usual care 
group (p= 0.0125). At 6 months, the mean change in HbA1c was -2.17% and 0.48% for the intervention and control groups respectively 
(p < 0.001). 
Conclusion: Pharmacists are effective at lowering HbA1c in primary care clinics, and patients were highly satisfied with these services. 
While direct revenue from this service did not meet cost, the pharmacist did positively affect outcomes that contribute to 
reimbursement. 
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BACKGROUND 
Diabetes mellitus is a prevalent and costly disease in the 
United States, which often results in costly micro- or macro-
vascular complications.1  In 2017, approximately 7.6% of the 
U.S. population (an estimated 24.7 million people) had 
diabetes. This cost an estimated $327 billion per year and is 
predicted to increase to $336 billion per year by 2034.2,3,4 
 
With this significant prevalence and cost, there is a necessity 
for collaboration between multiple healthcare professionals 
and specialties.  Pharmacists are uniquely positioned as 
medication experts to work collaboratively with other 
healthcare professionals and assist in drug therapy 
management which is key when managing a disease with 
multiple comorbidities such as diabetes. Pharmacists’ positive 
impact on diabetes management has been shown in a variety 
of settings. Some examples include pharmacist-led 
interventions demonstrating an additional HbA1c lowering of 
0.8% in an endocrinology clinic and of 1.2% in an internal 
medicine clinic. 5,6  This lower HbA1c correlates to lower rates  
of cardiovascular disease and greater cost savings for health 
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systems.7,8  As pharmacists have differing provider statuses 
throughout the world, their roles in these studies have varied 
greatly. Their duties could consist of providing medication 
counseling, lifestyle education, protocol-led medication 
recommendations, or immediate medication changes with 
independent prescribing rights.  
 
As the United States healthcare system continues to increase 
utilization of valued-based reimbursement strategies, a 
greater emphasis is placed on providing high quality care 
leading to high patient satisfaction.9  The two main quality 
programs currently in place are the STAR rating scale through 
the Center for Medicare & Medicaid Services (CMS) and the 
Healthcare Effectiveness Data and Information Set (HEDIS) 
measures through the National Committee for Quality 
Assurance. For both programs, high performing health systems 
receive bonus payments while low performing systems can 
expect a reduction in payment.10  Specifically for patients with 
diabetes, the STAR ratings and HEDIS measures both evaluate 
HbA1c levels (i.e. >9%, <9% or <7%).  The HEDIS measures also 
monitor the percentage of diabetic patients on statin therapy, 
while the STAR ratings also sets quality standards concerning 
the percentage of patients completing annual diabetic eye 
exams, provider monitoring of kidney function, maintaining 
controlled blood pressure, and adherence to diabetes 
medication regimens.11,12 
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To assess patient satisfaction, CMS also created surveys to 
assess patients’ experiences.  Patients receive satisfaction 
surveys after provider appointments [Clinicians and Group 
Consumer Assessment of Healthcare Providers and Systems 
(CG-CAHPS)] and hospital encounters [Hospital Consumer 
Assessment of Healthcare Providers and Systems (H-CAHPS) 
survey].13 Currently, only the H-CAHPS survey is linked to 
reimbursement; however, the CG-CAHPS survey may impact 
reimbursement in the furture.14 Since pharmacists are not yet 
providers in every state, CG-CAHPS surveys are not 
automatically sent out after office visits with the clinical 
pharmacists.  
 
The purpose of this study was to evaluate the impact of 
pharmacists’ services on diabetes management compared to 
usual care.  This will be assessed by evaluating the HbA1c, use 
of statin and aspirin therapy, and patient’s satisfaction with 
pharmacist’s services.  In addition, this study will begin to 
investigate the cost of providing clinical pharmacy services.  
 
METHODS 
Study Design 
The study consisted of two parts. The first part was a 
retrospective multi-clinic cohort of outpatients who had their 
diabetes managed by a primary care physician (PCP). These 
patients were seen every three to six months by their PCP. The 
PCPs managing this cohort of patients also had the option to 
refer patients to a clinical pharmacist for additional diabetes 
disease state management. The primary outcome of was 
change in HbA1c, compared between a group of patients 
receiving usual care alone and a group of patients receiving 
usual care with additional pharmacist-led disease state 
management. Pregnant women, insulin pump users, and 
patients being managed by a specialist (i.e. an endocrinologist) 
were not referred for pharmacist management. In order to 
match patients between the usual care and pharmacist-led 
disease state management groups, these patients were 
excluded from the usual care group. The second part of the 
study consisted of a cross-sectional survey evaluating patient 
satisfaction in patients receiving pharmacist-led disease state 
management. 
 
The inclusion criteria for the cohort was comprised of being 18 
years of age or older and having participated in two or more 
visits with the clinical pharmacist (pharmacist management 
group) or PCP (usual care group) during the study. The study 
had no exclusion criteria. 
 
Cohort Design 
The cohort was comprised of three internal medicine clinics in 
a single health system in northeast Ohio between July 17, 2015 
and October 14, 2016. It was divided into patients who only 
received usual care by their PCP and patients who received 
usual care but also received additional diabetes disease state 
management by a clinical pharmacist. The patients in the usual 
care group were managed by PCPs who either did not refer 
patients to or were under utilizers of clinical pharmacy 
services.  
 
Patients in the pharmacist management group were managed 
under a collaborative practice agreement with the patient’s 
PCP in the same clinic locations. Once the referral was placed 
by the PCP, the clinical pharmacist had the ability to order 
laboratory tests and initiate, discontinue, and adjust 
medications related to diabetes care. The clinical pharmacists’ 
activities included additional scheduled in-office visits and 
telephone calls to assess self-monitored blood glucose, HbA1c, 
and medication side effects, which could lead to medication 
regimen changes. All patients in the pharmacist management 
group participated in a 60 minute initial visit with the clinical 
pharmacist and 30 minute follow-up visits scheduled as 
needed at the discretion of the clinical pharmacist.  
 
At each pharmacist visit, the patients were vitalized, and the 
pharmacist would reconcile the patient’s medications, review 
the patient’s self-monitored blood glucose levels, and 
complete a symptoms assessment. The clinical pharmacist 
completed appropriate documentation in the electronic 
medical record and billed for the appointment utilizing facility 
fee codes 99212-99215 as incident to the PCP. PCPs were not 
involved with pharmacist visits. Based on this information, the 
pharmacist would develop an individualized plan, order 
necessary labs and medications, and provide education to the 
patient. Each pharmacist scheduled an average of 5-7 patients 
per half day of clinic (4 hours), and the pharmacists had 6-8 
half days of clinic each week. 
 
Data Collection 
Patients had their index visit recorded, which was defined as 
their first visit documented within the study period. All 
patients were followed for six months after their index visit. 
The study period was initially May 1, 2016 through October 31, 
2016. In the pharmacist management group, the index visit 
occurred between May 31, 2016 and October 14, 2016 and 
represented the first day the patient received pharmacist-led 
disease state management. In the usual care group the index 
visit occurred between July 17, 2015 and October 10, 2016. 
Due to the inclusion criteria of requiring at least two visits 
within the study period, the usual care group inclusion period 
was required to be extended to identify an appropriate 
number of patients for inclusion. 
 
Data collected from the index visit included gender, ethnicity, 
duration of diabetes, HbA1c, serum creatinine, presence of 
statin therapy, and BMI. Data collected at subsequent visits 
included HbA1c and presence of statin therapy. From October 
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2016 to November 2016, patients who were being seen by the 
same clinical pharmacists evaluated in the cohort were offered 
the opportunity to complete the optional, anonymous, 
abbreviated CG-CAHPS survey after one of their encounters 
with the pharmacist. There were no incentives, and the refusal 
to answer the survey was not met with any repercussions for 
the patients. 
 
Outcomes Analysis 
The primary outcome measured was change in HbA1c from 
baseline to six months post-index visit. Baseline HbA1c was 
defined as an HbA1c obtained either at the index visit or within 
three months prior to the index visit. Secondary outcomes 
were percent of patients with HbA1c <9% and 7% and 
presence of statin therapy from index visit to six-month post-
index visit. Change in HbA1c, percent of patients with HbA1c 
less than 9% and 7%, and presence of statin therapy were 
compared between the pharmacist-led disease state 
management group and the usual care group. Additional 
secondary outcomes included patient satisfaction from the 
CG-CAHPS survey and financial viability. Financial viability was 
evaluated only in the pharmacist management group and was 
measured by calculating the average reimbursement for 
appointments and multiplying this by the average number of 
patients seen per pharmacist for one year and subtracting the 
pharmacist’s salary and indirect costs. 
  
Statistical Analysis 
Data for this quasi-experimental two-arm study were imported 
into SPSSv24.0 software.  Demographic and other baseline 
summaries were stratified by study group.  Numeric data were 
tested for mean equality between study groups via 
independent samples Student’s t tests.  Categorical data were 
compared for distributional equality via Pearson chi-square or 
Fisher’s exact tests depending on cell sample size distribution.  
The primary outcome variable, hemoglobin A1c (%), was 
summarized at each post baseline study time point.  The 
primary analysis was a repeated measures ANOVA model with 
between-subjects effect for study group and within-subjects 
effect for post-baseline study time point.  The interaction 
effect for study group and time was not significant indicating 
no enhancement to the study group difference at either of the 
post-baseline time points.  Also, the effect of time was not 
significant indicating that the study group differences that 
were observed at 3 months were consistently maintained at 6 
months.  Therefore, overall means from the repeated 
measures ANOVA were produced and compared between 
study groups.   
 
As a supplemental sensitivity analysis, since repeated 
measures ANOVA requires data availability at both post-
baseline time points, the means between study groups were 
compared for equality at each post-baseline time point 
separately via independent samples Student’s t test.  There 
were no adjustments for multiple comparisons as this was an 
exploratory, sensitivity analysis.  Changes from baseline were 
also determined and tested for mean equality to zero within 
each group via paired samples Student’s t test.  The 
distribution of values below 7% and 9% cut-offs was also 
compared between groups via chi-square and Fisher’s exact 
tests.  A line graph stratified by study group was also produced 
with 95% confidence interval error bars to depict mean A1c 
across time.  To examine the potential confounding influence 
of baseline differences between groups, a multivariate linear 
regression model for A1c at 6 months post-baseline was 
determined with predictive factors for significant baseline 
differences and study group.  Finally, the secondary outcome 
of statin use at 6 months was compared for distributional 
equality between study groups via Pearson chi-square test.  All 
statistical testing was two-sided with p<0.05 considered 
statistically significant. 
 
RESULTS 
A total of 181 patients were included in this study, which 
included 112 patients in the pharmacist-led disease state 
management group and 69 in the usual care group. Of these 
patients, 99 and 98 in the pharmacist-lead disease state 
management group and 24 and 64 in the usual care group had 
three month and six month visits respectively. For this study, 
the average age of patients was 64 years in the pharmacist-led 
disease state management group and 62 years in the usual 
care group with an average duration of diabetes of over 12 
years in the pharmacist-led disease state management group 
and 10 years in the usual care group. In both groups, the 
majority of patients were African American and female. There 
were no significant differences between the groups except 
baseline HbA1c which was 10.1% in the pharmacist-led disease 
state management group and 9.3% in the usual care group 
(p=0.018) and number of patients on statin therapy (p < 0.05). 
A full account of this cohort’s baseline characteristics can be 
found in Table 1. 
 
Unadjusted change in HbA1c from baseline to six months post 
index visit showed greater decrease in the pharmacist-led 
disease state management group compared to the usual care 
group (-2.2 vs 0.5; p<0.001) (Figure 1). At six months post index 
visit, unadjusted results showed 32.1% of patients had HbA1c 
<7% in the pharmacist-led disease state management group 
versus 4.3% in the usual care group (P<0.0001). Similarly, at six 
months post index visit, unadjusted results showed 69.6% of 
patients in the pharmacist-led disease state management 
group had a HbA1c <9% versus 43.5% in the usual care group 
(p<0.0001) (Figure 2). 
 
Unadjusted statistics also showed an increase in statin therapy 
was seen at six months post index visit where 96% of patients 
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in the pharmacist-led disease state management group were 
on statin therapy compared to 80.6% of patients in the usual 
care group (p=0.001).  
Based on the abbreviated CG-CAHPS survey, patients were 
highly satisfied with pharmacist services. Pharmacist services 
were rated as “always” >90% of the time and were rated a 9/10 
or a 10/10 in 97.4% of cases (Table 2). After running the linear 
regression model adjusting for baseline HbA1c and statin use, 
pharmacist management showed a 6-month HbA1c lowering 
of 2.1 (p<0.001) independent of these baseline differences. 
 
The majority of patient visits were billed at 99213 (level 3) or 
99214 (level 4). The clinics no show rates average 21-31% 
depending on location, and a financial model was run to 
estimate financial viability using hard dollar reimbursement.  
In order to assess financial viability, a model was created for 
two FTEs of a PharmD. It was assumed that, divided amongst 
them, they completed 14 half days of clinic per week. Once no 
show and cancelled appointments are subtracted from the 
total, approximately 2500 patient visits per year are 
conducted. Of these appointments, approximately 90% were 
billed at a level three or four. Based on the revenue received 
by the health system, approximately 75% of each PharmD’s 
salary and benefits are covered by this revenue. This estimate 
does not include additional income sources for the PharmD 
such as quality-based outcome reimbursement from CMS, 
reimbursement for residency training, compensation for 
precepting pharmacy students, or reimbursement for being 
shared faculty within a college of pharmacy. 
 
Discussion 
The HbA1c lowering results of our study reflect results that 
have been reported in the past literature. Pharmacist 
management of diabetes was effective at lowering HbA1c. In 
this study, a larger number of patients were also able to reach 
HbA1c goals set by the CMS star rating scale and the HEDIS 
measures (<7% and <9%) in the pharmacist management 
group. This not only is associated with better cardiovascular 
outcomes for patients but also leads to increased cost savings 
for health systems and increased reimbursement from CMS 
and managed care organizations. While the reimbursement 
directly tied to the pharmacist services are below costs, the 
health system will decrease cost through less diabetic 
complications and increase revenue through these quality-
based reimbursement pathways. When all of this is 
considered, this study showed a pharmacist’s ability to 
significantly contribute to quality based reimbursement and 
cost savings for health systems when they manage patients 
with diabetes.  
 
While patient satisfaction is not currently utilized to affect 
reimbursement in the outpatient setting, CMS may move in 
that direction in the future. As such, a pharmacist’s results on 
a patient satisfaction survey, such as the CG-CAHPS, may have 
future monetary repercussions. The results of this study show 
that pharmacists score higher than the average scores 
reported by the CAHPS database.8 
 
Limitations 
In this study, the higher HbA1c at baseline in the pharmacist-
led disease state management group compared to the usual 
care group was a limitation, but the effects of this difference 
was minimized through the use of logistic regression. It may be 
possible to show a more significant lowering in HbA1c due to 
this difference, but the study also showed that more patients 
were able to obtain goal HbA1c’s (<7% and <9%) in the 
pharmacist management group.  Being able to bring more 
patients to their goal HbA1c shows the efficacy of pharmacist 
management despite the difference in baseline HbA1c. There 
was also a fluctuation in the number of in the usual care group 
at 3 months. This was likely due to the providers in the 
evaluated clinics often requesting 6-month follow-up with 
their patients without consideration for current HbA1c. Lastly, 
the CG-CAHPS survey has not been validated to assess 
pharmacist services, but in this study, pharmacists are filling a 
similar role to primary care providers, who the survey was 
validated for. Also, the survey that was offered to patients was 
an abbreviated CG-CAHPS survey. The investigators chose to 
include only those questions that were more likely to be 
influenced by the person providing the clinical services. If the 
CG-CAHPS survey is used in the future for reimbursement, the 
scores on the other questions that were omitted would also be 
included.  
 
Another limitation includes the need to extend the inclusion 
period for the usual care patients in the cohort. This led to 
patients in the usual care group being included for an 
additional 9 months. This is a concern for adding additional 
variable as new diabetes medications could have been 
released, services available in individual clinics could have 
changed, and changes in support staff could have occurred. 
While this is true, care for any individual patient is unlikely to 
be dramatically affected. To further elucidate the point, during 
the time period in question, no new novel classes of diabetes 
medications received FDA approval, which means the average 
patient would have the same medication options despite this 
difference. 
 
CONCLUSION 
Pharmacist management of diabetes, compared to usual care, 
in primary care clinics led to a significant reduction in HbA1c, 
which is associated with decreased rates of cardiovascular 
events and increased reimbursement from CMS. Patients were 
also highly satisfied with the service provided. While revenue 
from pharmacy services was slightly below costs, the HbA1c 
lowering seen is associated with increased quality-based 
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reimbursement and cost savings for the health system. If these 
cost savings and increased quality-based reimbursements are 
taken into consideration, providing pharmacist services is a 
cost-effective way to assist physicians in improving control of 
patients’ diabetes. 
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Table 1: Baseline Characteristics 
  
Intervention  
(n = 112) 
Control  
(n = 69) 
Gender: Male 
n (%) 
42 
(37.5%) 
26 
(37.7%) 
Ethnicity: African American  
n (%) 
92 
(82.1%) 
55 
(79.7%) 
Age, years 
Mean (Std) 
64.1 
(9.59) 
61.8 
(13.2) 
BMI,  kg/m2 
Mean (Std) 
34.4 
(7.7) 
34.9 
(9.1) 
Duration of diabetes, years 
Mean (Std) 
12.4 
(10.4) 
10.4 
(7.5) 
Number of patients on statin 
therapyA 
n (%) 
98 
(87.5%) 
50 
(72.5%) 
Serum creatinine, 
mg/dL Mean (Std) 
1.07 
(0.43) 
1.09 
(0.40) 
HbA1cA 
Mean (Std) 
10.1 
(2.0) 
9.3 
(2.2) 
Number of patients with 
HbA1c <7%  
n (%) 
3 
(2.7) 
3 
(4.3) 
Number of patients with 
HbA1c <9%A 
n (%) 
34 
(30.4) 
36 
(52.2) 
A: P-value less than 0.05. 
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Table 2: CG-CAHPS Survey Results. Responding “always” or 9/10 or 10/10. 
 
Question Responses for 
Pharmacist 
Services  
(n=80) 
CG-CAHPS 2015 
Average Scores14 
When calling this provider’s office, how often were questions 
answered the same day? 
92.4% 57% 
How often did the provider explain things in a way that was easy to 
understand? 
98.7% 91% 
How often did the provider listen carefully to you? 100% 93% 
How often did the provider seem to know important information 
about your medical history? 
98.8% 85% 
How often did this provider show respect for what you had to say? 100% 95% 
How often did this provider spend enough time with you? 98.8% 92% 
How often did this provider’s office follow up to give you the results 
of a test? 
92.1% 85% 
How would you rate this provider from 0 to 10 with 10 being the 
best provider possible? 
97.4% 83% 
Footnote: Currently, for the H-CAHPS survey, only a response of “always” or a 9/10 or 10/10 contributes positively 
financially for health systems, which led to the results being reported as such. 
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Figure 1: Change in Mean HbA1c (95% CI) 
 
 
 
 
 
Figure 2: Percent of Patients with HbA1c <7% and <9%. 
 
 
Footnote: There was a statistically significant difference between both groups at each time point except  
HbA1c <7% at index visit. 
